Skip to main content

Leukemia, lymphoma, and myeloma.

83 Phase 1 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Leukemia, lymphoma, and myeloma83 studies

Acute Myeloid LeukemiaPhase 1NCT03113643Papers

SL-401

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dana-Farber Cancer InstituteOpen the brief

Untreated Nodal T Follicular Helper Cell LymphomaPhase 1NCT07278856

Ruxolitinib + CHOP

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

City of Hope Medical CenterOpen the brief

Multiple MyelomaPhase 1NCT07581704

Sirolimus

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Christopher StrouseOpen the brief

Recurrent Acute Lymphoblastic LeukemiaPhase 1NCT05418088

Anti-CD19/CD20/CD22 CAR T-Cells

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Sumithira VasuOpen the brief

AML/MDSPhase 1NCT04318678Papers

CD123-CAR T

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

St. Jude Children's Research HospitalOpen the brief

Acute Myeloid Leukemia and Other Myeloid MalignanciesPhase 1/2NCT06928662

Decitabine + FLAG-Ida and Total-Body Irradiation

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer CenterOpen the brief

Acute Myeloid LeukemiaPhase 1NCT07374029

DC/AML Fusion Vaccine

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

David AviganOpen the brief

Large B-Cell Lymphoma (LBCL)Phase 1NCT07361224Papers

RhDNase I

Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion

Tel-Aviv Sourasky Medical CenterOpen the brief

Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsPhase 1/2NCT04797767Papers

Venetoclax Plus CLAG-M

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of WashingtonOpen the brief

B-cell Lymphoma RefractoryPhase 1/2NCT07319676Papers

CART

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

National University Hospital, SingaporeOpen the brief

Relapsed/Refractory Multiple MyelomaPhase 1/2NCT06536413Papers

ATRA With Carfilzomib

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

The Methodist Hospital Research InstituteOpen the brief

Relapsed or Refractory Hodgkin Lymphoma and CD30+ LymphomasPhase 1NCT05544968

CD30 Bispecific Antibody-Armed T Cells

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Medical College of WisconsinOpen the brief

Acute Myeloid LeukemiaPhase 1NCT03533816Papers

EAGD T-cell

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Medical CenterOpen the brief

Acute Myeloid LeukemiaPhase 1NCT05748197Papers

ADCLEC.syn1 CAR T cells

ADCLEC.syn1 in People With Acute Myeloid Leukemia

Memorial Sloan Kettering Cancer CenterOpen the brief

Clinical trials: Phase 1 and Phase 2, explained